Santoro Armando, Masini Silvia, Cavina Raffaele, Tronconi Maria Chiara, De Vincenzo Fabio
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy.
Front Oncol. 2023 Jul 31;13:1205720. doi: 10.3389/fonc.2023.1205720. eCollection 2023.
The use of immune checkpoint inhibitors (ICIs) for treating several types of cancer is increasing, but they may be associated with immune-related adverse events (irAEs). Pancreatitis is a rare irAE, mostly responsive to steroid treatment. There are no published data on the management of steroid-refractory ICI-induced pancreatitis. Rituximab has shown efficacy in the setting of relapsing non-ICI-induced autoimmune pancreatitis. However, its use has not been tested for treating immunotherapy-related pancreatitis. Here, we present the case of a patient with steroid-refractory immune-related pancreatitis successfully treated with rituximab as a potential strategy for irAE management.
免疫检查点抑制剂（ICI）用于治疗多种类型癌症的情况日益增多，但它们可能与免疫相关不良事件（irAE）有关。胰腺炎是一种罕见的irAE，大多对类固醇治疗有反应。关于类固醇难治性ICI诱导的胰腺炎的管理，目前尚无已发表的数据。利妥昔单抗在复发性非ICI诱导的自身免疫性胰腺炎的治疗中已显示出疗效。然而，其用于治疗免疫治疗相关胰腺炎的效果尚未得到检验。在此，我们报告一例类固醇难治性免疫相关胰腺炎患者成功接受利妥昔单抗治疗的病例，作为irAE管理的一种潜在策略。
